Overview

SHR-1701 Combined With Fluzoparib in a Single-arm, Extended Clinical Trial for Maintenance Treatment of Advanced Lung Squamous Cell Carcinoma After First-line Treatment

Status:
Not yet recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the trial was to evaluate the efficacy and safety of SHR-1701 combined with fluzopar as a maintenance therapy after first-line treatment of advanced lung squamous cell carcinoma. Patients with advanced or metastatic (stage IV) lung squamous cell carcinoma have not received systemic chemotherapy and have measurable lesions (RECIST 1.1) ECOG PS 0-1. The patient received SHR1701 +fluzoparib
Phase:
Phase 2
Details
Lead Sponsor:
Hunan Province Tumor Hospital